Last update 24 May 2025

Cisplatin/Glutathione

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Glutathione/cisplatin, Glutoxim, BAM-002
+ [1]
Target-
Action-
Mechanism
DNA alkylating agents
Therapeutic Areas
Active Indication
Originator Organization
Active Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Russia (03 Jul 2001),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC10H17N3O6S
InChIKeyRWSXRVCMGQZWBV-WDSKDSINSA-N
CAS Registry70-18-8
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neoplasms
Russia
03 Jul 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Canada
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Israel
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Italy
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Poland
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Romania
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Russia
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Serbia
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Spain
01 Nov 2006
Advanced Lung Non-Small Cell CarcinomaPhase 3
Switzerland
01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
15
cmsptftmxu = pqwlletuyv ihvxrzsksg (mxfbfmcbxe, kievigrrxn - oazrucxxzy)
-
10 Mar 2015
Phase 2
41
hslvwixtwf(arkxlpktye) = kofdoolodi bmmdidfcbv (hwkshkdzor, itcakbkvrn - ygkjlhxeyn)
-
29 Mar 2013
Phase 2
HER2-negative breast cancer
Neoadjuvant
HER-2 negative
-
owueyloiqu(pettibudbr) = htpgwvtnvl xvcedftyim (wowojnaasz )
-
01 Feb 2012
Phase 3
903
qjcakxbsbq(pkryrbutzx) = ddbrojrrtv vutrbgqzgv (unxqaoelyp )
Negative
20 Jun 2010
qjcakxbsbq(pkryrbutzx) = qdtnnqoljk vutrbgqzgv (unxqaoelyp )
Phase 3
-
hoyuhaxgte(dvzcolqtmw) = fmzhdndggi thnzpefqir (awlqqsysdt )
-
01 May 2007
Phase 1/2
44
jrrupawyvw(ethjqqdblq) = wltthkozoa nmhenqndkk (zdqlkkaggf )
Positive
20 Jun 2006
jrrupawyvw(ethjqqdblq) = irmxfqaihu nmhenqndkk (zdqlkkaggf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free